Objective: The aim of this feasibility study is to evaluate the use of tranexamic acid and its safe use alongside standard therapy in dogs with primary immune thrombocytopenia (ITP).Design: This is a cohort feasibility study involving 10 dogs diagnosed with primary ITP that received standard therapy for ITP including corticosteroids, a single dose of vincristine, and omeprazole. Dogs were randomly divided into either the control group (n = 6) or the group receiving tranexamic acid (TXA group, n = 4).Key findings: The mean time from the start of treatment until remission was 5 days in the TXA group and 6 days in the control group (P = 0.69). Two dogs, one in each group, did not achieve remission. Clinical bleeding scores were not significantly different between both groups (p = 0.43), and the median blood volume administered was 37.5 ml/kg for the TXA group and 9.72 ml/kg for the control group (p = 0.084). Three out of the four dogs receiving TXA of 20 mg/kg IV started vomiting within 15 min of administration and were given a reduced dose of 15 or 10 mg/kg IV.Conclusion: Tranexamic acid did not confer a clinical benefit in this small cohort study and was associated with a high incidence of vomiting. This study provides useful information for the design of future trials in dogs with ITP receiving tranexamic acid including outcome measures and safety.

Chronic inflammatory enteropathy (CIE) has historically been divided into food-responsive chronic inflammatory enteropathy (CIE-FR), immunosuppressant-responsive chronic inflammatory enteropathy (CIE-IR), non-responsive chronic inflammatory enteropathy (CIE-NR) and antibiotic-responsive chronic inflammatory enteropathy (CIE-AR). Given the rising concern for antimicrobial resistance (AMR) and the effects of antibiotics on the microbiome, replacement of CIE-AR with microbiota-modulation-responsive enteropathy (MrMRE) has been suggested, and antibiotic use questioned. The objective of this study was to assess the prescribing habits of antibiotics for dogs with CIE prior to referral. This was a single-centre retrospective study of cases between 2020 and 2024 assessing antibiotic prescription for CIE in the six months prior to referral. Data including signalment, clinical signs, diagnosis, antibiotic administration and the antibiotics used were recorded. A total of 144 dogs with chronic inflammatory enteropathy were included, of which 128 had CIE without protein-losing enteropathy (PLE) and 16 had PLE. Overall, 57.6% of dogs with CIE referred for investigation were prescribed antibiotics in the six months prior to referral. Of the dogs prescribed antibiotics, metronidazole was the most prescribed (74.7%), followed by amoxicillin-clavulanate (36.1%). Dogs with diarrhoea were more likely to be prescribed antibiotics overall and were also more likely to receive metronidazole. Antibiotic use differed across the years, with the lowest rate prescribed in 2024 (26/46 [56.5%] in 2020/2021, 24/33 [72.7%] in 2022, 22/35 [62.9%] in 2023, and 11/30 [36.7%] in 2024; p = 0.031). Further work is required to understand continued antibiotic use in CIE and inform antimicrobial stewardship strategies.